Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumours

in Endocrine-Related Cancer
View More View Less
  • 1 O De Rycke, Gastroenterology and Pancreatology , Hopital Beaujon, Clichy, France
  • 2 T Walter, Digestive Oncology, Groupement Hospitalier Edouard Herriot, Lyon, France
  • 3 M Perrier, Gastroenterology and Digestive Oncology, CHU Reims, Reims, France
  • 4 O Hentic, Gastroenterology and Pancreatology, Hopital Beaujon, Clichy, France
  • 5 C Lombard-Bohas, Digestive Oncology, Groupement Hospitalier Edouard Herriot, Lyon, France
  • 6 R Coriat, Gastro enterology and digestive oncology, Hopital Cochin, Paris, France
  • 7 G Cadiot, Gastroenterology and Digestive Oncology, Hopital Robert Debré, Reims, France
  • 8 A Couvelard, Department of Pathology, Beaujon-Bichat University Hospitals, PARIS, France
  • 9 P Ruszniewski, Gastroenterology and Pancreatology, Hopital Beaujon, Clichy, France
  • 10 J Cros, Pathology, Beaujon Hospital - Paris Diderot University - INSERM U1149, Clichy, France
  • 11 L De Mestier, Department of Gastroenterology, Beaujon University Hospital (APHP), Clichy, France

Correspondence: Louis De Mestier, Email:
Restricted access

A rechallenge is common after initial efficacy of alkylating-based chemotherapy (ALK) in pancreatic neuroendocrine tumors (PanNET). High MGMT expression seems associated with lower response to ALK. We aimed to evaluate the efficacy and toxicity of ALK rechallenge in PanNET. Secondly, to assess the evolution of MGMT expression under ALK. All consecutive patients with advanced PanNETs who received initial ALK (achieving tumor control) followed by a pause > 3 months, then an ALK rechallenge (ALK2) upon progression were retrospectively studied (Cohort A). Primary endpoint was progression-free survival under ALK2 (PFS2). The MGMT expression was retrospectively assessed by immunohistochemistry (H-score) in consecutive PanNET surgically resected following ALK (Cohort B). We foud that cohort A included 62 patients (median Ki67 8%), for which ALK1 followed by pause achieved an objective response rate of 55%, and a PFS1 of 23.7 months (95% IC, 19.8-27.6). ALK2 achieved no objective response, and stability in 62% of patients. The median PFS2 was 9.2 months (IC 95% 7.1-11.3). At multivariable analysis, a hormonal syndrome (p=0.032) and a pause longer than 12 months (p=0.041) were associated with a longer PFS2. In the cohort B (17 patients), the median MGMT H-score increased from 45 (IQR 18-105) before ALK, to 100 (IQR 56-180) after ALK (p=0.003). We conclude that after initial efficacy of ALK treatment, a pause followed by ALK rechallenge might be appropriate to prolong tumor control, improve quality of life and limit long-term adverse events. Increased MGMT expression under ALK might explain low efficacy of ALK rechallenge.


Society for Endocrinology